Filtros de búsqueda

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

artículo científico publicado en 2016

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

artículo científico publicado en 2020

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

artículo científico publicado en 2017

A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma

artículo científico publicado en 2014

A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma

artículo científico publicado en 2016

A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen

artículo científico publicado en 2003

Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab

scientific article published on 01 February 2020

Abstract 2402: GITR cancer immunotherapy: Epitope swapping of anti-GITR TRX518 to inform functional translatability from mouse to human

scholarly article

Abstract 2711: Rational combination of GITR agonism with PD-1 blockade

scholarly article

Abstract 3735: An anti-tumor immune response is evoked by partial-volume single dose radiation

scholarly article

Abstract 4041: Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC

scholarly article

Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models

scholarly article

Abstract 978: Tim-4+ tissue-resident macrophages impair antitumor T-cell immunity

scholarly article

Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma

scholarly article

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

article

Abstract LB-081: A nuclear cAMP microdomain functions as a tumor suppressor in melanoma

scholarly article

Acquired resistance to immunotherapy in MMR-D pancreatic cancer

scientific article published on 20 November 2018

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors

artículo científico publicado en 2018

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

scientific article published on 18 December 2018

Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins

scientific article published on 14 June 2018

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

artículo científico

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

scientific article published on 07 August 2019

Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains

artículo científico publicado en 2006

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

scientific article published on 21 March 2019

Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells ⬇️

artículo científico publicado el 1 de marzo de 2013

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity

artículo científico publicado en 2006

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

artículo científico publicado en 2010

Alan Houghton ⬇️

artículo científico publicado el 27 de marzo de 2012

Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity ⬇️

artículo científico publicado el 10 de septiembre de 2010

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

artículo científico publicado en 2018

Altered development of NKT cells, γδ T cells, CD8 T cells and NK cells in a PLZF deficient patient

artículo científico publicado en 2011

Altered self: the not-so-neo-antigens

artículo científico publicado en 2018

An Anti-Tumor Immune Response is Evoked By Partial-Volume Single Dose Radiation in Two Murine Models

artículo científico publicado en 2018

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity

artículo científico publicado en 2016

An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

artículo científico publicado en 2016

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

scientific article published on 01 April 2019

Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice

artículo científico publicado en 2014

Anatomic position determines oncogenic specificity in melanoma

artículo científico publicado en 2022

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

artículo científico publicado en 2010

Anti-GITR antibodies--potential clinical applications for tumor immunotherapy

artículo científico publicado el 1 de diciembre de 2010

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine

artículo científico publicado en 2007

Antibody therapy of cancer

artículo científico publicado en 2012

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Antigens recognized by autologous antibodies of patients with soft tissue sarcoma

artículo científico publicado en 2005

Antitumour immunity gets a boost

artículo científico publicado en 2014

Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma ⬇️

artículo científico publicado en 2011

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

artículo científico publicado en 2016

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy ⬇️

artículo científico publicado el 10 de mayo de 2013

Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness

artículo científico publicado en 2022

Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

artículo científico publicado en 2019

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

artículo científico publicado en 2016

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

artículo científico publicado en 2016

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

artículo científico publicado en 2016

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy

artículo científico publicado en 2011

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types ⬇️

artículo científico publicado el 1 de marzo de 2013

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment

artículo científico publicado en 2013

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment.

artículo científico publicado en 2014

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment

artículo científico publicado en 2017

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

artículo científico publicado en 2020

CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology.

artículo científico publicado en 2015

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

artículo científico publicado en 2020

CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytes

artículo científico publicado en 2004

CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.

artículo científico publicado en 2005

CMET-11. LEPTOMENINGEAL MELANOMA METASTASIS PRESENTING AS INTRAVENTRICULAR AND SUBARACHNOID HEMORRHAGE

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

artículo científico publicado en 2014

CTLA-4 antibodies: new directions, new combinations.

artículo científico publicado en 2014

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

artículo científico publicado en 2008

CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems

artículo científico publicado en 2004

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

artículo científico publicado en 2011

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

artículo científico publicado en 2015

Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies

artículo científico publicado en 2017

Cancer immunotherapy using checkpoint blockade.

artículo científico publicado en 2018

Cancer's off switch

scientific article published on 01 May 2014

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

artículo científico publicado en 2018

Characterization of computed tomography scan abnormalities in patients with biopsy-proven hepatic metastases from uveal melanoma

artículo científico publicado en 2011

Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia

artículo científico publicado en 2021

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions ⬇️

artículo científico publicado el 1 de octubre de 2013

Checkpoint inhibition and melanoma: Considerations in treating the older adult

artículo científico publicado en 2017

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

artículo científico publicado en 2016

Chromatin states define tumour-specific T cell dysfunction and reprogramming.

artículo científico publicado en 2017

Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling

artículo científico publicado en 2003

Classification of current anticancer immunotherapies

artículo científico publicado en 2014

Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review

artículo científico publicado en 2015

Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists

artículo científico

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

artículo científico publicado en 2013

Clinical benefit and toxicity of nivolumab plus ipilimumab in patients with advanced melanoma previously treated with checkpoint blockade inhibitors. ⬇️

scholarly article

Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma

artículo científico publicado en 2016

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

artículo científico publicado en 2016

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion

artículo científico publicado en 2016

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

artículo científico publicado en 2016

Combination immunotherapy: a road map.

artículo científico publicado en 2017

Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.

artículo científico publicado en 2014

Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice ⬇️

artículo científico publicado el 22 de marzo de 2011

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

artículo científico publicado en 2014

Combinatorial Cancer Immunotherapies

artículo científico publicado en 2016

Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

artículo científico publicado en 2016

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

artículo científico publicado en 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

scientific article published on 01 September 2015

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

artículo científico publicado en 2016

Combining cancer immunotherapy and targeted therapy ⬇️

artículo científico publicado el 2 de abril de 2013

Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles

artículo científico publicado en 2005

Completely regressed cutaneous melanocytic lesion: was it benign or was it malignant?

artículo científico publicado en 2009

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

artículo científico publicado en 2014

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma

artículo científico publicado en 2013

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

scientific article published on 08 September 2020

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

artículo científico publicado en 2020

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21 ⬇️

artículo científico publicado el 1 de noviembre de 2003

Correction to: Strategies for Predicting Response to Checkpoint Inhibitors

artículo científico publicado en 2019

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Correction: Frequent MAGE Mutations in Human Melanoma.

artículo científico publicado en 2010

Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy

artículo científico publicado en 2010

Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

scientific article published on 01 December 2016

Curbing Tregs' (Lack of) Enthusiasm

artículo científico publicado en 2017

Current topics in melanoma

artículo científico publicado en 2007

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

artículo científico publicado en 2014

Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right

artículo científico publicado en 2009

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

artículo científico publicado en 2010

DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation.

artículo científico publicado en 2006

DNA vaccines against cancer.

artículo científico publicado en 2006

DNA vaccines for melanoma

artículo científico publicado en 2005

DNA vaccines: an active immunization strategy for prostate cancer

artículo científico publicado en 2003

Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

artículo científico publicado en 2016

Defining the critical hurdles in cancer immunotherapy

artículo científico publicado en 2011

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment

artículo científico publicado en 2016

Depression, cytokines, and pancreatic cancer

artículo científico publicado en 2013

Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope

artículo científico publicado en 2011

Determinants of COVID-19 disease severity in patients with cancer

artículo científico publicado en 2020

Determinants of Severity in Cancer Patients with COVID-19 Illness

artículo científico publicado en 2020

Development of effective vaccines for old mice in a tumor model

artículo científico publicado en 2008

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

artículo científico publicado en 2013

Different Faces of Hepatotoxicity in Patients With Metastatic Melanoma on Combination Vemurafenib and Ipilimumab Therapy ⬇️

scholarly article

Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma

artículo científico publicado en 2004

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy.

artículo científico publicado en 2015

Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database

artículo científico publicado en 2009

Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease

artículo científico

Dual mode reflectance and fluorescence confocal laser scanning microscopy for in vivo imaging melanoma progression in murine skin

artículo científico publicado en 2005

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

artículo científico publicado en 2017

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

artículo científico publicado en 2014

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial

artículo científico publicado en 2014

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

artículo científico

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

artículo científico publicado en 2016

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

artículo científico publicado en 2015

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

article

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

artículo científico publicado en 2018

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.

artículo científico publicado en 2018

Emerging therapies in melanoma

artículo científico publicado el 1 de noviembre de 2012

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

artículo científico publicado en 2014

Enhanced responses to tumor immunization following total body irradiation are time-dependent

artículo científico publicado en 2013

Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients

scientific article published on October 2013

Erratum: Correlationof clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.

artículo científico publicado en 2010

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

artículo científico publicado en 2016

Evidence generation and reproducibility in cell and gene therapy research: A call to action

artículo científico publicado en 2021

Expanded access programmes: patient interests versus clinical trial integrity

artículo científico publicado en 2014

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model

F-18 FDG PET/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma

artículo científico publicado en 2018

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

artículo científico publicado en 2013

First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

scientific article published on 04 October 2019

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab

scientific article published on 25 July 2019

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

artículo científico publicado en 2019

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial

artículo científico publicado en 2015

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation

artículo científico publicado en 2017

Frequent MAGE Mutations in Human Melanoma ⬇️

artículo científico publicado el 16 de septiembre de 2010

Fundamental immune-oncogenicity trade-offs define driver mutation fitness

artículo científico publicado en 2022

Future cancer research priorities in the USA: a Lancet Oncology Commission

artículo científico publicado en 2017

GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability

artículo científico publicado en 2013

GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines

scientific article published on 01 January 2002

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

article

Genetic basis for clinical response to CTLA-4 blockade

article

Genetic basis for clinical response to CTLA-4 blockade in melanoma

artículo científico publicado en 2014

Genetics and immunology: reinvigorated

artículo científico publicado en 2015

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring

artículo científico publicado en 2020

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

artículo científico publicado en 2018

Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma

artículo científico publicado en 2015

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

artículo científico publicado en 2009

Health-related quality of life results from the phase III CheckMate 067 study.

artículo científico publicado en 2017

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

artículo científico publicado en 2017

Hepatotoxicity with combination of vemurafenib and ipilimumab

artículo científico publicado en 2013

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.

artículo científico publicado en 2017

Hiding the road signs that lead to tumor immunity

artículo científico publicado en 2011

How can we tell when cancer vaccines vaccinate?

artículo científico publicado en 2003

ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity

artículo científico publicado en 2020

IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?

artículo científico publicado en 2015

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation

artículo científico publicado en 2015

Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics

artículo científico publicado en 2005

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

artículo científico publicado en 2017

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

artículo científico publicado en 2011

Immigration in science

scientific article published on 01 November 2020

Immune checkpoint blockade

artículo científico publicado en 2014

Immune modulation in cancer with antibodies

artículo científico publicado en 2013

Immune regulatory antibodies: are they the next advance?

artículo científico publicado en 2010

Immune rejection of mouse tumors expressing mutated self.

artículo científico publicado en 2009

Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

artículo científico publicado en 2020

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

artículo científico publicado en 2018

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

artículo científico publicado en 2015

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy

artículo científico publicado en 2015

Immunity to cancer through immune recognition of altered self: studies with melanoma

artículo científico publicado en 2003

Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity

artículo científico publicado en 2003

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI).

artículo científico publicado en 2015

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

artículo científico publicado en 2016

Immunologic correlates of the abscopal effect in a patient with melanoma

artículo científico publicado en 2012

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

artículo científico publicado en 2010

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma

artículo científico publicado en 2013

Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma.

artículo científico publicado en 2013

Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes

artículo científico publicado en 2007

Immunomodulatory therapy for melanoma: Ipilimumab and beyond ⬇️

artículo científico publicado el 1 de marzo de 2013

Immunotherapy and the belly of the beast

artículo científico publicado en 2014

Immunotherapy of Melanoma

artículo científico publicado en 2015

Immunotherapy of Melanoma: Facts and Hopes

artículo científico publicado en 2019

Immunotherapy: The path to win the war on cancer?

artículo científico publicado en 2015

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

artículo científico publicado en 2020

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment.

artículo científico publicado en 2014

Improved Endpoints for Cancer Immunotherapy Trials ⬇️

artículo científico publicado el 8 de septiembre de 2010

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

artículo científico publicado en 2010

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma

scientific article published on December 2008

Improving the therapeutic benefits of ipilimumab

artículo científico publicado el 1 de diciembre de 2010

In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors

scientific article published on 22 July 2019

In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide

artículo científico publicado en 2016

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

artículo científico publicado en 2013

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

artículo científico publicado en 2016

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4.

artículo científico publicado en 2013

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

artículo científico publicado en 2013

Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue

artículo científico publicado el 19 de julio de 2002

Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination

artículo científico publicado en 2005

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype

artículo científico publicado en 2012

Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child

artículo científico publicado en 2021

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

artículo científico publicado en 2015

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

scientific article published on 25 February 2016

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

scientific article published on 01 April 2017

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

artículo científico publicado en 2011

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

artículo científico publicado en 2016

Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells

artículo científico publicado en 2017

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

artículo científico publicado en 2017

Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading

scientific article published on 24 September 2019

Introducing a New Series: Immunotherapy Facts and Hopes

artículo científico publicado en 2018

Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name

artículo científico publicado en 2018

Ipilimumab and whole brain radiation therapy for melanoma brain metastases

artículo científico publicado en 2014

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

artículo científico publicado en 2010

Ipilimumab for patients with advanced mucosal melanoma

artículo científico publicado en 2013

Ipilimumab in patients with cancer and the management of dermatologic adverse events

artículo científico

Ipilimumab in patients with melanoma and autoimmune disease

artículo científico publicado en 2014

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial ⬇️

artículo científico publicado el 27 de marzo de 2012

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

artículo científico publicado en 2009

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

artículo científico publicado en 2011

Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response

artículo científico publicado en 2013

Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy

article

KIT as a therapeutic target in metastatic melanoma

artículo científico publicado en 2011

Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.

artículo científico publicado en 2008

Keratoacanthomas associated with imatinib mesylate ⬇️

artículo científico publicado el 26 de noviembre de 2010

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

artículo científico publicado en 2016

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial

artículo científico publicado en 2017

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection

artículo científico publicado en 2013

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy

artículo científico publicado en 2014

Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade

artículo científico publicado en 2020

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

artículo científico publicado en 2020

Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial

artículo científico publicado en 2003

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.

artículo científico publicado en 2018

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

artículo científico publicado en 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

artículo científico publicado en 2018

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi).

artículo científico publicado en 2014

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

artículo científico publicado en 2017

Mechanisms of immunization against cancer using chimeric antigens

artículo científico publicado en 2008

Meeting report: fourth international congress of the Society for Melanoma Research.

artículo científico publicado en 2008

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

artículo científico publicado en 2017

Melanoma vaccines

artículo científico publicado en 2002

Metastasis and immune evasion from extracellular cGAMP hydrolysis

scientific article published on 28 December 2020

Modulation of CTLA-4 and GITR for cancer immunotherapy

artículo científico publicado en 2011

Modulation of GITR for cancer immunotherapy ⬇️

artículo científico publicado el 12 de enero de 2012

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

artículo científico publicado en 2018

Monoclonal antibodies in cancer therapy

artículo científico publicado en 2012

Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment

artículo científico publicado en 2011

Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications

artículo científico publicado en 2016

Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma.

artículo científico publicado en 2011

Multiple pathways to tumor immunity and concomitant autoimmunity

artículo científico publicado en 2002

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma

scientific article published on 17 May 2018

Myeloid-derived suppressor sells and the efficacy of CD8(+) T-cell immunotherapy

artículo científico publicado en 2013

Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience

scientific article published on 25 March 2019

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

artículo científico publicado en 2018

Neoantigen quality predicts immunoediting in survivors of pancreatic cancer

artículo científico publicado en 2022

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

artículo científico publicado en 2022

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.

artículo científico publicado en 2017

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

artículo científico publicado en 2017

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

artículo científico publicado en 2015

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

artículo científico publicado en 2017

Nivolumab plus ipilimumab in advanced melanoma

artículo científico publicado en 2013

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

artículo científico publicado en 2018

Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity

artículo científico publicado en 2018

Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity

artículo científico publicado en 2018

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

artículo científico publicado en 2011

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

artículo científico publicado en 2009

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

artículo científico

Opportunistic infections in patients treated with immunotherapy for cancer

artículo científico publicado en 2014

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

scientific article published on 01 August 2019

Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses

artículo científico publicado en 2009

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

artículo científico publicado en 2006

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

artículo científico publicado en 2017

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

artículo científico publicado en 2016

PD-1 Blockers

artículo científico publicado en 2015

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

scientific article published on 29 July 2019

PD-L1 Blockade Therapy: Location, Location, Location

scientific article published on 01 November 2020

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

artículo científico publicado en 2018

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor

artículo científico publicado en 2014

Patient perspectives on ipilimumab across the melanoma treatment trajectory

artículo científico publicado en 2017

Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?

artículo científico publicado en 2012

Patient-Physician Communication in the 21st Century.

artículo científico publicado en 2016

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

artículo científico publicado en 2014

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

artículo científico publicado en 2015

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

artículo científico publicado en 2011

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

artículo científico publicado en 2017

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

artículo científico publicado en 2015

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab.

artículo científico publicado en 2014

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

artículo científico publicado en 2013

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

artículo científico publicado en 2018

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

artículo científico publicado en 2015

Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope

artículo científico publicado en 2002

Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma ⬇️

artículo científico publicado el 1 de abril de 2003

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.

artículo científico publicado en 2008

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma ⬇️

artículo científico publicado el 5 de agosto de 2012

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

scientific article published on 18 February 2015

Phase II study of extended-dose temozolomide in patients with melanoma

artículo científico publicado en 2008

Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma

artículo científico publicado en 2006

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

artículo científico publicado en 2003

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

artículo científico publicado en 2008

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

scientific article published on 26 February 2013

Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma.

artículo científico publicado en 2017

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

artículo científico publicado en 2016

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

artículo científico publicado en 2017

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

artículo científico publicado en 2015

Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer

scientific article published on 28 March 2019

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer

artículo científico publicado en 2014

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy

artículo científico publicado en 2018

Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients

artículo científico publicado en 2015

Pre-treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

artículo científico publicado en 2010

Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab

artículo científico publicado en 2014

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

artículo científico publicado en 2016

Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy

scientific article published on 28 November 2018

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

artículo científico publicado en 2016

Progression of RAS-mutant leukemia during RAF inhibitor treatment

artículo científico publicado en 2012

Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors

artículo científico publicado en 2020

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

artículo científico publicado en 2016

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab ⬇️

artículo científico publicado en 2016

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer ⬇️

artículo científico publicado en 2019

Putting the Immunologic Brakes on Cancer

artículo científico publicado en 2018

RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

artículo científico publicado en 2016

RECIST 1.1-Update and clarification: From the RECIST committee.

artículo científico publicado en 2016

Radiotherapy after surgical resection for head and neck mucosal melanoma.

artículo científico publicado en 2010

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma

artículo científico publicado en 2013

Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus

artículo científico publicado en 2008

Rapid eradication of a bulky melanoma mass with one dose of immunotherapy

artículo científico publicado en 2015

Rational design of anti-GITR-based combination immunotherapy

scientific article published on 29 April 2019

Reassessing the usual suspects causing a commotion in the blood (and vessels?).

artículo científico publicado en 2004

Recombinant Human Interleukin-7 (CYT107) Enhances CD4 and CD8 T Cell Recovery Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant In Patients with Myeloid Malignancies ⬇️

artículo científico publicado en 2010

Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation ⬇️

artículo científico publicado el 25 de septiembre de 2012

Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?

scientific article published on 01 September 2019

Refusing to TAP out: 16 new human TEIPPs identified

scientific article published on 21 August 2018

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas ⬇️

artículo científico publicado el 13 de noviembre de 2012

Reply to A. Indini et al

artículo científico publicado en 2016

Reply to M. Nishino

artículo científico publicado en 2016

Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.

artículo científico publicado en 2015

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.

artículo científico publicado en 2018

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

artículo científico publicado en 2016

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

artículo científico publicado en 2013

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor ⬇️

artículo científico publicado el 1 de diciembre de 2011

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma

artículo científico publicado en 2009

Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma

artículo científico publicado en 2007

Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors

artículo científico publicado en 2020

Safety of Infusing Ipilimumab Over 30 Minutes

scientific article published on 29 June 2015

Selecting antigens for cancer vaccines

scientific article published on 10 April 2012

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

artículo científico publicado en 2004

Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids

scientific article published on 19 September 2019

Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.

artículo científico publicado en 2009

Shared cancer neoantigens: Making private matters public.

artículo científico publicado en 2017

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

artículo científico publicado en 2010

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

artículo científico publicado en 2016

Stage-IV melanoma and pulmonary metastases: factors predictive of survival

artículo científico publicado en 2007

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

artículo científico publicado en 2015

Strategies for Predicting Response to Checkpoint Inhibitors

artículo científico publicado en 2018

Strategies to overcome immune ignorance and tolerance.

artículo científico publicado en 2002

Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?

artículo científico publicado en 2016

Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literature

artículo científico publicado en 2007

Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

scientific article published on 17 December 2019

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma

T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks

artículo científico publicado en 2014

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression

artículo científico publicado en 2016

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

artículo científico publicado en 2017

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma

scientific article published on 01 January 2021

Targeting T Cell Co-receptors for Cancer Therapy

artículo científico publicado en 2016

Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers

artículo científico publicado en 2010

Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

artículo científico publicado en 2016

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

artículo científico publicado en 2014

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

artículo científico publicado en 2005

The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime? ⬇️

artículo científico publicado el 15 de febrero de 2012

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

artículo científico

The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells.

artículo científico publicado en 2015

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

artículo científico publicado en 2015

The abscopal effect associated with a systemic anti-melanoma immune response

artículo científico publicado en 2012

The delicate balance of melanoma immunotherapy

artículo científico publicado en 2013

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

artículo científico publicado en 2016

The future of cancer immunotherapy: microenvironment-targeting combinations

artículo científico publicado en 2020

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

artículo científico publicado en 2016

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

artículo científico publicado en 2016

The hallmarks of successful anticancer immunotherapy

artículo científico publicado en 2018

The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases

artículo científico publicado en 2008

The importance of animal models in tumor immunity and immunotherapy

artículo científico publicado en 2014

The many faces of the anti-COVID immune response

artículo científico publicado en 2020

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

artículo científico publicado en 2008

The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein

artículo científico publicado en 2016

The role of lipopolysaccharide in T-cell responses following DNA vaccination

scientific article published on 01 March 2003

The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword

artículo científico publicado en 2005

Therapeutic implications of the emerging molecular biology of uveal melanoma.

artículo científico publicado en 2011

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab

artículo científico publicado en 2016

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.

artículo científico publicado en 2016

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.

artículo científico publicado en 2018

Treatment of locally recurrent mucosal melanoma with topical imiquimod

artículo científico publicado en 2011

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

scientific article published on 09 September 2019

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines

artículo científico publicado en 2004

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

artículo científico publicado en 2019

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

artículo científico publicado en 2015

Two Distinct Categories of Focal Deletions in Cancer Genomes

artículo científico publicado en 2013

Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo

artículo científico publicado en 2006

Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma

artículo científico publicado en 2006

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

artículo científico publicado en 2010

Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors.

artículo científico publicado en 2017

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

scientific article published on 08 June 2010

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda